Quality of life after colorectal cancer treatment
Official title: Quality Of Life In Colorectal Cancer Survivors
Run by Institute of Oncology Ljubljana · NCT07427901 · Data updated 2026-11-12
This project will test whether late side effects at 6, 12, and 24 months affect quality of life in people aged 25–65 who completed initial treatment for colorectal cancer at the Institute of Oncology Ljubljana.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 368 (estimated) |
| Sponsor | Institute of Oncology Ljubljana Academic / other |
| Locations | 1 site (Ljubljana) |
| Status | Recruiting |
| Started | May 1, 2023 |
| Main results expected | January 1, 2024 |
| Study ends | December 31, 2027 |
| Registry record updated | February 23, 2026 |
| Trial ID | NCT07427901 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are working-capable adults aged 25–65 with colon or rectal cancer who received their first oncological treatment at the Institute of Oncology Ljubljana and can complete follow-up questionnaires and consent.
✕Probably not a fit
People outside the 25–65 age range, those unable to complete questionnaires or attend follow-up visits, and patients treated elsewhere are unlikely to benefit directly from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The study follows colorectal cancer survivors at 6, 12, and 24 months after their first oncological treatment to identify late adverse effects that may influence quality of life. Participants complete validated questionnaires covering physical, psychological, and social well-being, while researchers record diagnosis and specific treatments received. The prevalence of late adverse effects will be measured and analyzed for associations with cancer type and treatment modalities. Findings will be used to map common long-term problems and inform supportive care at the treating institution.
Why it matters
Potential benefit: If successful, the findings could help clinicians identify and manage late side effects to improve long-term quality of life for colorectal cancer survivors.
How similar studies have gone: Previous follow-up studies have identified common long-term effects after colorectal cancer, so this approach builds on established research while providing local, treatment-specific data.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with colorectal cancer (colon or rectal cancer) * Age 25 to 65 years * First oncological treatment performed at the Institute of Oncology Ljubljana * Working-capable patients * Ability to complete questionnaires * Ability to provide written informed consent Exclusion Criteria: * Age \< 25 years or \> 65 years * Patients unable to complete questionnaires * Patients unable to participate in follow-up assessments * Patients who do not provide written informed consent
Where it's running
-
Institute of Oncology Ljubljana
Ljubljana, Slovenia Recruiting
Study contacts
- Study coordinator: Klavdija Korošec
- Email: kkorosec@onko-i.si
- Phone: +386 31630065
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Fruquintinib plus FOLFIRI for second-line metastatic colorectal cancer
This study will test whether adding fruquintinib to FOLFIRI helps people with metastatic colorectal cancer who progressed after first-line FOLFOX plus bevacizumab.
-
Evaluating a new CAR T-cell therapy for solid tumors expressing EGFR
This study is testing a new CAR T-cell therapy to see if it can safely help adults with certain solid tumors, like colorectal and lung cancer, that have specific markers.
-
Evaluating a new CAR T-cell therapy for solid tumors expressing MSLN
This study is testing a new CAR T-cell therapy to see if it can safely treat adults with solid tumors like colorectal and lung cancer that express a specific protein.
-
Comparing single-incision and conventional laparoscopic surgery for colorectal cancer outcomes
This study is testing if a newer type of surgery with one small cut can help people with colorectal cancer have less pain and better healing compared to the usual surgery with multiple cuts.
-
LTZ-232: a first-in-human test in advanced colorectal and other solid tumors
A first-in-human study tests LTZ-232, a new therapy for adults with unresectable or metastatic colorectal cancer and other solid tumors that have not responded to standard treatments.
-
DEM301 in advanced colorectal cancer: a first-in-human test
This first-in-human Phase 1 study tests DEM301 in adults with advanced metastatic colorectal cancer to see if it is safe, how it behaves in the body, and whether it shows any signs of activity.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.